Nikhil KamathTwo Pharma Giants Who'd Never Met | Mankind & Dr. Reddy's | WTF is Pharma?
At a glance
WHAT IT’S REALLY ABOUT
Inside India’s pharma engine: generics, innovation gaps, and founder opportunities
- Rajeev Juneja explains how Mankind scaled via a contrarian, bottom-up go-to-market strategy—starting in small towns, prioritizing deep coverage, affordability, and brand-building through OTC visibility.
- G.V. Prasad breaks down pharma’s core segments (branded generics, APIs, biologics, CDMO) and demystifies how generics are approved by proving bioequivalence rather than “copying a recipe.”
- They argue that India is the “pharmacy of the world” mainly by volume because global profits concentrate with innovators and downstream players, while post-patent generic prices collapse dramatically (especially in the US).
- The discussion highlights structural gaps: India’s strength in small-molecule chemistry versus relative weakness in biologics/peptides, alongside China’s rapid creation of an innovation ecosystem through long-horizon policy, talent repatriation, and risk capital.
- For entrepreneurs, they caution against capital-heavy plays like online pharmacy and suggest more viable openings in wellness/sexual health brands, GLP-1 adjacent services (counseling + lifestyle), AI-for-pharma tooling, CDMO/China-plus-one opportunities, and unglamorous infrastructure like expired-medicine destruction and traceability.
IDEAS WORTH REMEMBERING
5 ideasMankind’s edge came from avoiding the incumbent battlefield.
Juneja attributes Mankind’s early scaling to a bottom-up approach—starting in Western UP, then expanding gradually—while pricing products more affordably for smaller-town ecosystems where bigger players had weak coverage.
In India, ‘generics’ are mostly branded generics driven by trust and distribution muscle.
They note ~95% of India’s market behaves like branded FMCG: doctors choose among many equivalent brands based on rep reach/relationships, perceived reliability, and price positioning rather than purely molecule identity.
Generic ‘sameness’ is proven through bioequivalence, not just chemical copying.
Prasad emphasizes matching the innovator’s blood concentration-time curve within acceptable ranges; formulation choices (excipients, release characteristics) materially affect performance even when the API is identical.
Quality standards may be similar globally; enforcement and supply-chain handling create perceived differences.
They dispute simplistic claims that India allows lower purity, arguing standards are broadly aligned but enforcement, packaging, temperature control, and brand quality systems can influence real-world outcomes and perceptions.
India captures global pharma volume, but innovators and downstream players capture most value.
Because India sells largely post-patent generics, US prices can drop ~95%+ after multiple entrants; this keeps India’s revenue share small despite massive output.
WORDS WORTH SAVING
5 quotesHere's the thing nobody tells you. India is called the pharmacy of the world, but that's by volume. By revenue, we're barely a rounding error. We make the drugs, but someone else makes the money.
— Nikhil Kamath
I had safety incidents where, you know, people died, and that really shook me up and really put me in a deep state of depression.
— G.V. Prasad
What you hate, um, becomes a big lesson for you.
— Rajeev Juneja
No, I really loved it because, you know, it's like magic. You take simple molecules, combine them to make complex molecules, and suddenly this molecule cures a disease.
— G.V. Prasad
When people start the business, the problem is what? They copy a set formula... Never, ever follow a set formula.
— Rajeev Juneja
High quality AI-generated summary created from speaker-labeled transcript.
